Adipose-derived Stem CellsNCT07690501
Adipose-derived Stem Cells Combined With Excimer Light in the Treatment of Stable Vitiligo
A study testing Adipose-derived Stem Cells Combined With Excimer Light in people with Adipose-derived Stem Cells and Excimer Light, run by Tanta University at 1 site in Egypt.
Trial summary
This study aimed to assess the efficacy and safety of intradermal injection of adipose-derived stem cells, alone and combined with excimer light in treatment of stable vitiligo. Read more about this study
- Who is it for?
- Ages 15 to 52 years
- Conditions the study is for
- Adipose-derived Stem Cells, Excimer Light, Stable Vitiligo
- What is being tested?
- Adipose-derived Stem Cells Combined With Excimer Light
- Type of treatment
- Surgery or procedure
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 15 participants
- Where
- 1 siteEgypt
- Study dates
- 1 Aug 2023to 1 Sep 2025
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 15 to 52 years
- All sexes
- No healthy volunteers
- Child, Adult
Who may be able to join
- Patients with two or more similar patches of stable vitiligo "absence of new patches of depigmentation or enlargement of the pre-existing patches" for 6 months at least.
- Patients who will accept to be enrolled in the study and will sign an informed consent.
Who cannot join
- Unstable vitiligo for more than 6 months.
- Current bacterial or viral infection in the treatment area.
- Patients with unrealistic expectation.
- Very thin patients "poor donor areas".
- Patients with uncontrolled systemic disease such as diabetes or hypertension.
- Patients with hepatitis B or C virus infection.
Show all 10Show fewer
- Patients with any other skin disease.
- Patients with bleeding or coagulopathy disorders.
- Pregnancy and lactation.
- Patients who received topical treatment for vitiligo during the last month, or systemic treatment during the past three months before the study.
Trial locations and contacts
1 site in 1 country.
About this study
This study aimed to assess the efficacy and safety of intradermal injection of adipose-derived stem cells, alone and combined with excimer light in treatment of stable vitiligo.
Read the detailed description
Vitiligo is a common disfiguring autoimmune disease that negatively affects patients' self-esteem and quality of life. Vitiligo is caused by a dynamic interplay between genetic and environmental risks that initiates an autoimmune attack on melanocytes in the skin.
Adipose tissue-derived stem cells have the capacity to secrete a variable cytokines and growth factors, including hepatocyte growth factor (HGF), interleukin-6 (IL-6), macrophage colony-stimulating factor (M-CSF), transforming growth factor-β1 (TGF-β1), tumour necrosis factor (TNF), vascular endothelial growth factor (VEGF), that stimulate angiogenesis, tissue remodeling, and anti-apoptotic processes. Phototherapy has an eminent effect on stoppage of progression and repigmentaion of vitiligo patches. Narrowband ultraviolet B (NB-UVB) and ultraviolet A (UVA), and monochromatic excimer light (MEL) can be used in treatment of vitiligo. The specific 308-nm radiation wavelength is delivered in a targeted form by the xenon-chloride excimer laser and is also available in an incoherent form that is commonly referred to as the excimer lamp.
- Conditions
- Adipose-derived Stem Cells, Excimer Light, Stable Vitiligo
- Being tested
- Adipose-derived Stem Cells Combined With Excimer Light
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Adipose-derived Stem Cells Combined With Excimer LightProcedure or surgery
All patients received adipose-derived stem cells combined with excimer light.
| Study group | Role | What they receive |
|---|---|---|
| Study group | Experimental | Patients with two or more similar patches of stable vitiligo "absence of new patches of depigmentation or enlargement of the pre-existing patches" for 6 months at least Receives: Procedure: Adipose-derived Stem Cells Combined With Excimer Light |
What is being measured
The primary outcome is the main question the study is designed to answer.
Vitiligo Disease Activity (VIDA) Score
The Vitiligo Disease Activity (VIDA) Score is a 6-point clinical scale used to measure the progression or stability of vitiligo.
The scale ranges from -1 to +4, where higher numbers indicate more recent and rapid disease activity:
- 4: Active disease (new lesions or expansion) within the last 6 weeks.
- 3: Active disease between 6 weeks and 3 months.
- 2: Active disease between 3 and 6 months.
- 1: Active disease between 6 and 12 months. 0: Stable disease with no changes for 1 year or longer.
- 1: Stable for 1 year or longer, showing signs of spontaneous repigmentation
Measured: 6 months post-procedure
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted8 Jul 2026
- Study start1 Aug 2023
- Primary completion1 Sep 2025
- Study completion1 Sep 2025
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Adipose-derived Stem CellsStudies of the same condition, open and under way.
- More trials run by Tanta UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 15 participants (actual)
Sponsor and investigators
- Lead sponsor
- Tanta University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Samar El-Sayed Abdel Hamid Gad, Tanta University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07690501
- Sponsor's protocol ID
- 36264MD92/5/23
- Status last verified
- Jul 2026
- First submitted
- 1 Jul 2026
- Last updated
- 8 Jul 2026
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: The data will be available upon a reasonable request from the corresponding author after the end of study for one year.
Study at a glance
From the registry record, last updated by the sponsor on 8 Jul 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Adipose-derived Stem Cells Combined With Excimer Light in the Treatment of Stable Vitiligo
- ClinicalTrials.gov ID
- NCT07690501
- Acronym / sponsor ID
- 36264MD92/5/23
- Conditions
- Adipose-derived Stem Cells, Excimer Light, Stable Vitiligo
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 15 participants (actual)
- Lead sponsor
- Tanta UniversityUniversity, hospital or other
- Study start
- 1 Aug 2023 (actual)
- Primary completion
- 1 Sep 2025 (actual)
- Study completion
- 1 Sep 2025 (actual)
- First posted
- 8 Jul 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study aimed to assess the efficacy and safety of intradermal injection of adipose-derived stem cells, alone and combined with excimer light in treatment of stable vitiligo.
Detailed description
Vitiligo is a common disfiguring autoimmune disease that negatively affects patients' self-esteem and quality of life. Vitiligo is caused by a dynamic interplay between genetic and environmental risks that initiates an autoimmune attack on melanocytes in the skin.
Adipose tissue-derived stem cells have the capacity to secrete a variable cytokines and growth factors, including hepatocyte growth factor (HGF), interleukin-6 (IL-6), macrophage colony-stimulating factor (M-CSF), transforming growth factor-β1 (TGF-β1), tumour necrosis factor (TNF), vascular endothelial growth factor (VEGF), that stimulate angiogenesis, tissue remodeling, and anti-apoptotic processes. Phototherapy has an eminent effect on stoppage of progression and repigmentaion of vitiligo patches. Narrowband ultraviolet B (NB-UVB) and ultraviolet A (UVA), and monochromatic excimer light (MEL) can be used in treatment of vitiligo. The specific 308-nm radiation wavelength is delivered in a targeted form by the xenon-chloride excimer laser and is also available in an incoherent form that is commonly referred to as the excimer lamp.
Study design
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Study group | Experimental | Procedure: Adipose-derived Stem Cells Combined With Excimer LightPatients with two or more similar patches of stable vitiligo "absence of new patches of depigmentation or enlargement of the pre-existing patches" for 6 months at least |
Who may qualify
- Ages
- 15 to 52 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult
Key inclusion criteria (2 listed)
- Patients with two or more similar patches of stable vitiligo "absence of new patches of depigmentation or enlargement of the pre-existing patches" for 6 months at least.
- Patients who will accept to be enrolled in the study and will sign an informed consent.
Key exclusion criteria (10 listed)
- Unstable vitiligo for more than 6 months.
- Current bacterial or viral infection in the treatment area.
- Patients with unrealistic expectation.
- Very thin patients "poor donor areas".
- Patients with uncontrolled systemic disease such as diabetes or hypertension.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Adipose-derived Stem Cells Combined With Excimer LightAll patients received adipose-derived stem cells combined with excimer light. | Procedure or surgery | Study group |
Primary outcome
Vitiligo Disease Activity (VIDA) Score
Time frame: 6 months post-procedure
The Vitiligo Disease Activity (VIDA) Score is a 6-point clinical scale used to measure the progression or stability of vitiligo. The scale ranges from -1 to +4, where higher numbers indicate more recent and rapid disease activity: * 4: Active disease (new lesions or expansion) within the last 6 weeks. * 3: Active disease between 6 weeks and 3 months. * 2: Active disease between 3 and 6 months. * 1: Active disease between 6 and 12 months. 0: Stable disease with no changes for 1 year or longer. * 1: Stable for 1 year or longer, showing signs of spontaneous repigmentation
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 8 Jul 2026.
- Individual participant dataSharing planned: Yes. The data will be available upon a reasonable request from the corresponding author after the end of study for one year.
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Adipose-derived Stem Cells Combined With Excimer Light in people with Adipose-derived Stem Cells and Excimer Light, run by Tanta University at 1 site in Egypt.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 10 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 8 Jul 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Vitiligo Disease Activity (VIDA) Score (time frame: 6 months post-procedure). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 8 Jul 2026; AzTrials last refreshed its copy on 2 Nov 2026.